Intravenous Immunoglobulin (IVIG), also referred to as Immunoglobulin (Ig) replacement therapy, is a product made from antibodies collected from the plasma of healthy individuals. Antibodies are proteins in the blood that help fight infections. Plasma is collected from 10,000 to 50,000 individuals with normal immune systems and given to strengthen the recipient's immune system and fight infections.

IVIG is used in multiple conditions, including immune deficiencies, autoimmune diseases, and some neurological conditions. Immunoglobulins can be administered intravenously or subcutaneously.

For myeloma patients, IVIG is usually administered every three to four weeks at a dose of 0.4 grams per kilogram. The frequency of IVIG administration may vary based on the individual's steady-state immunoglobulin levels. For patients who see a significant reduction of plasma cells during or after their treatment, IVIG is usually recommended to restore/supplement their immune system as much as possible.

For myeloma patients on bispecific antibody therapy, IVIG is used to treat hypogammaglobulinemia (low antibody levels) to reduce the risk of infection.

While IVIG can be hit/miss in terms of insurance coverage, when required in a medical setting and considered medically necessary, Medicare and other private insurance providers are very likely to cover the cost. Find more financial and helpful resources here, or contact our Financial Program Manager at myfinancialcoach@healthtree.org.

Learn more about IVIG therapy with HealthTree University for Multiple Myeloma: